STAMPEDE Five Year Follow-up Results

A five year follow-up of the STAMPEDE abiraterone comparison has been completed, and the results demonstrate that previously reported effects are robust. It shows that future results are unlikely to change meaningfully with further follow-up. The initial results of the STAMPEDE advanced prostate cancer trial showed that progression-free survival is improved when abiraterone acetate and prednisone (AAP) are added to androgen deprivation therapy. For further details related to the follow-up results, please see this article published 12th April 2022 -


Systemic Therapy in Advancing or Metastatic Prostate cancer: Evaluation of Drug Efficacy

See the latest News in STAMPEDE through the link to the right.